Perrigo, Catalent get generic of Teva inhaler approved on 4th go-round

Perrigo and Catalent are releasing a limited supply of Perrigo's newly approved generic of the Teva ProAir HFA inhaler and are ramping up production for the fourth quarter of 2020. (Perrigo)

It took four tries over four years, but Perrigo has finally gotten over the finish line with its generic of Teva’s tricky-to-make ProAir HFA inhaler for chronic obstructive pulmonary disease and asthma.  

Perrigo and its manufacturing partner Catalent touted the news jointly today, saying they are releasing a limited supply now of the generic albuterol sulfate inhalation aerosol and ramping up production for a steady supply by the fourth quarter of 2020. 

The inhaler is approved for patients four years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. 


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: FDA rejects Perrigo knockoff of Teva's ProAir inhaler for third time

"This is a significant technical achievement for both parties, as it is the first generic metered-dose inhaler to be approved by the FDA in over 20 years," Jonathan Arnold, Catalent president of oral and specialty delivery, said in a statement. 

The product is being produced at Catalent’s North Carolina inhaler plant. 

Perrigo said drug tracker IQVIA measured ProAir HFA gross sales for the previous 12 months at $1.4 billion, although Teva reported (PDF) 2019 sales of only $274 million, down 23%. Teva has two other ProAir products including one with a mobile app, the ProAir Digihaler, approved a year ago.

Teva settled a patent challenge by Perrigo over ProAir HFA in 2014, allowing it to launch its generic. But it wasn’t that simple. Perrigo received three complete response letters, one each in 2016, 2017 and 2018, during its journey to get its product up to FDA expectations. The last rejection forced Perrigo to restate earnings. 

Teva in 2017 also settled a patent fight with Lupin for the inhaler product, but the Indian company has yet to get its effort to the FDA.

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.